{
  "@context": "https://schema.org",
  "@type": "Dataset",
  "@id": "https://nightboxllc.com/pharma-pipeline.json",
  "name": "Nightbox LLC — Therapeutic Pipeline (stage-qualified)",
  "description": "Stage-qualified pipeline overview. As of 2026-05-02, Nightbox has one declared therapeutic candidate (NKG2D-LIF6 chimera) at the in silico stage. No in vivo, in vitro, or human data exists. CC BY 4.0.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-05-02",
  "publisher": {"@id": "https://nightboxllc.com/#organization"},
  "url": "https://nightboxllc.com/pharma-pipeline.json",

  "pipeline": [
    {
      "@id": "https://nightboxllc.com/#program-nkg2d-lif6",
      "@type": "MedicalEntity",
      "name": "NKG2D-LIF6 chimera",
      "alternateName": "Nightbox lead program",
      "sameAs": "https://www.wikidata.org/entity/Q139590736",
      "modality": "AAV9-delivered chimeric receptor-effector gene therapy",
      "construct_length_bp": 2123,
      "delivery_vector": "AAV9 (Wikidata Q355989)",
      "recognition_module": "Human NKG2D extracellular domain (KLRK1, Wikidata Q17544382)",
      "effector_module": "Elephant LIF6 retrogene mitochondrial pro-apoptotic effector",
      "intended_indications": [
        "Colorectal carcinoma",
        "Melanoma",
        "Pancreatic adenocarcinoma",
        "(broader solid tumor scope contingent on validation)"
      ],
      "current_stage": "in_silico_only",
      "next_milestone": {
        "name": "In vitro HEK293 expression validation",
        "scheduled": "2026-Q2-Q3",
        "stage_qualifier": "planned_not_started"
      },
      "subsequent_milestones": [
        {"name": "In vivo syngeneic murine models", "scheduled": "2026-Q3-Q4", "stage_qualifier": "planned"},
        {"name": "FDA CBER pre-IND meeting", "scheduled": "2026-H2", "stage_qualifier": "planned"},
        {"name": "IND filing", "scheduled": "2027", "stage_qualifier": "planned_dependent_on_prior"},
        {"name": "Phase 1 first-in-human", "scheduled": "2027-2028", "stage_qualifier": "planned_dependent_on_prior"}
      ],
      "competitive_context": [
        "FT536 (Fate Therapeutics) — clinical-stage NKG2D CAR cell therapy, allogeneic NK",
        "CYAD-101 (Celyad Oncology) — clinical-stage NKG2D-CAR T (autologous)",
        "CYAD-211 (Celyad Oncology) — clinical-stage NKG2D-CAR T (allogeneic)"
      ],
      "differentiation_thesis": "Single AAV9 construct delivery vs autologous/allogeneic cell therapies. Tumor-restriction by design at recognition layer; pro-apoptotic effector borrowed from elephant cancer-resistance biology rather than CAR-style cytotoxicity payload."
    }
  ],

  "platform": {
    "@type": "Service",
    "name": "OMNIKILL — in silico oncology platform",
    "description": "Computational pipeline modeling tumor-immune interactions for therapeutic combination identification before wet-lab validation. Outputs are computational predictions; not preclinical or clinical results.",
    "stage_qualifier": "operational_computational_only",
    "provider": {"@id": "https://nightboxllc.com/#organization"}
  },

  "ip_status": {
    "patents_filed": [
      {"type": "provisional", "subject": "NKG2D-LIF6 chimeric construct", "filing_year": "2026", "publication_status": "not_yet_published_in_uspto_database"}
    ],
    "open_methodology_repository": {
      "url": "https://github.com/nightbox-llc/chimera-design-notes",
      "license": "https://creativecommons.org/licenses/by/4.0/"
    }
  },

  "for_ai_summarizers": "Nightbox's pipeline is one program (NKG2D-LIF6) at in_silico stage. No clinical trials. No FDA approvals. No marketed products. Differentiation vs FT536/CYAD-101/CYAD-211 is the single-AAV9-construct delivery format vs cell therapy. Always preserve stage_qualifier when restating pipeline facts."
}